HARTFORD, Conn.–(BUSINESS WIRE)–For first time, Humana offering Medicare Advantage plans in Connecticut.
Author: Business Wire
Kubota Vision Receives ISO 13485:2016 Certification
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company r…
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
SKYGEN Appoints Jason Grendahl as New Chief Client Success Officer
MENOMONEE FALLS, Wis.–(BUSINESS WIRE)– #dental–Jason Grendahl joins leading dental solutions innovator SKYGEN as Chief Client Success Officer to further boost customer success.
有關四年研究的新資料顯示，中外製藥的Enspryng可長期減少泛視神經脊髓炎 (NMOSD)患者的復發
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO: 4519)公布了關於Enspryng® [學名：satralizumab（基因重組藥）]長期有效性和安全性的新資料。Enspryng是中外製藥研究生產的一種pH依賴性結合抗IL-6受體人類化單株抗體。資料顯示，Enspryng具有良好的風險/獲益特徵，在抗水通道蛋白-4抗體(AQP4-IgG)血清陽性的泛視神經脊髓炎（NMOSD，一種影響中樞…
Neue Vierjahresdaten zeigen anhaltende Rezidivreduktion durch Chugais Enspryng bei Menschen mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab neue längerfristige Wirksamkeits- und Sicherheitsdaten für Enspryng® [generischer Name: Satralizumab (genetische Rekombination)] bekannt, einen pH-abhängig bindenden humanisierte…
De nouvelles données sur quatre ans indiquent une réduction durable des rechutes grâce à l’Enspryng de Chugai chez des patients atteints du trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé de nouvelles données d’efficacité et de sécurité d’emploi à long terme concernant Enspryng® [nom générique : satralizumab (recombinaison génétique)], anticorps monoclonal …
Resumen: Nuevos datos correspondientes a cuatro años muestran una reducción sostenida de las recaídas gracias a Enspryng de Chugai en personas con trastorno del espectro de la neuromielitis óptica
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado nuevos datos de eficacia y seguridad a largo plazo de Enspryng® [nombre genérico: satralizumab (recombinación genética)], un anticuerpo monoclonal humanizado contra el r…
jCyte Announces Expansion of Role for Chief Commercial Officer Samir Mody
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, today announced the expansion of the role of Dr. Samir Mody. In addition to his Chief …
Samenvatting: Nieuwe vierjarige gegevens tonen aanhoudende vermindering van terugval door Chugai’s Enspryng bij mensen met neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft nieuwe gegevens over de werkzaamheid en veiligheid op langere termijn aangekondigd voor Enspryng® [generieke naam: satralizumab (genetische recombinatie)], een pH-afhankelijke …
Riassunto: Nuovi dati quadriennali mostrano una riduzione sostenuta delle recidive nei trattamenti con Enspryng di Chugai delle persone affette da disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha reso noti nuovi dati riguardanti la sicurezza e l’efficacia a lungo termine di Enspryng® [nome generico: satralizumab (ricombinazione genetica)], un anticorpo monoclonale umanizza…
Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
GENEVA–(BUSINESS WIRE)–Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Newly Launched Division of Kriya Therapeutics
REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya Therapeutics announced the appointment of Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release thir…
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the grant of induc…
New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced new longer-term efficacy and safety data for Enspryng® [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclona…
Contact Lenses Markets, 2026 by Modality (Reusable, v/s Disposable), Design (Spherical, Toric, Multifocal & Others), Material Type (Silicon Hydrogel, Hydrogel, Others) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Contact Lenses Market, By Modality (Reusable, v/s Disposable), By Design (Spherical, Toric, Multifocal & Others), By Material Type (Silicon Hydrogel, Hydrogel, Others), By Application, By Distribution Channel, B…
FGX International Celebrates World Sight Day by Announcing 17 Million Pairs of Donated Glasses
SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, a leading eyewear designer and manufacturer, celebrates 14 years of partnership with RestoringVision, the world’s largest nonprofit provider of reading glasses to people in need. Through this long-s…
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced results from a new analysis of UPLIZNA® (inebilizumab-cdon) in neuromyelitis optica spectrum disorder (NMOSD).
Global Phenylephrine Hydrochloride Market Insights (2021 to 2026) – Key Analysis and Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Phenylephrine Hydrochloride Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type” report has been added to ResearchAndMarkets.com’s offering. This rep…